COMPUGEN LTD. : Compugen Presents Prediction Based Discovery Strategy 4-traders ... within the infrastructure and has resulted to date in multiple discoveries, such as the previously disclosed CGEN-928 with potential use for late stage, aggressive and drug resistant multiple myeloma and Rituximab resistant non-Hodgkin's lymphoma. |
